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Background/aim: The aim of this study was to evaluate if the modified ACEF (age, creatinine, and ejection fraction) score is a predictor
of major adverse cardiac and cerebrovascular events during 1 year of follow-up in patients with ST-segment elevation myocardial
infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).
Materials and methods: We retrospectively enrolled 1632 consecutive patients who were admitted to our emergency department
diagnosed with STEMI within 12 h of chest pain and treated with primary PCI. The modified ACEF score, determined with a simplified
scoring system, was calculated. The patients were grouped into tertiles according to this score (group I mACEF < 1.03, group II mACEF
1.03–1.37, group III > 1.37) . The clinical and angiographic data were compared among the tertiles.
Results: In patients with the highest mACEF tertile, out-of-hospital cardiac arrest (1.3%, 1.8%, and 4.1% consecutively; P = 0.003), Killip
class ≥ II (P < 0.001), and cardiogenic shock were more common and ejection fraction was lower (P < 0.001). Moreover, in the 1-year
follow-up, there was a statistically significant difference between cardiac mortality, target vessel revascularization, stroke, reinfarction,
and major adverse cardiac and cerebrovascular events of the groups, while the rates of stent thrombosis were similar.
Conclusion: The modified ACEF score is a predictor of cardiac mortality and morbidity during 1-year follow-up.
Key words: Acute ST-elevation myocardial infarction, ACEF score, mortality

1. Introduction
The incidence of ST-segment elevation myocardial
infarction (STEMI) has been increasing over the last two
decades and it continues to be a significant public health
problem throughout the world (1). Primary percutaneous
coronary intervention (p-PCI) has become the treatment
of choice for acute STEMI, as it improves both in-hospital
and long-term mortality. Despite this improvement,
in-hospital mortality rates are reported to be as high
as 7%–10% in some registry reports (2). Therefore,
risk stratification is essential for clinical decision and
management. Various risk scores such as Thrombolysis
in Myocardial Infarction (TIMI), GRACE, and ZWOLLE
have been applied (3–5). Besides angiographic variables,
clinical data, such as the presence of anemia and renal
impairment, are independent risk factors for in-hospital
cardiovascular mortality.
The modified ACEF (age, creatinine, and ejection
fraction) score is a simple scoring system calculated with
basic data and associated with renal dysfunction and
* Correspondence: arzukalayci@yahoo.com
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clinical adverse events during follow-up after treatment
for myocardial infarction (MI) and complex coronary
interventions (6). The aim of this study was to evaluate
whether the mACEF is a predictor of major adverse cardiac
and cerebrovascular events during 1 year of follow-up in
patients treated with p-PCI for acute STEMI.
2. Materials and methods
2.1. Study population
We retrospectively evaluated 1910 patients who were
admitted to our center with STEMI within 12 h of chest
pain and treated with p-PCI between January 2007 and
June 2010. One hundred forty-four patients who lacked
one or more of the variables required to calculate the
modified ACEF score were excluded. Additionally, 134
patients were excluded due to absence of follow-up records.
The remaining 1632 patients formed the study population.
The inclusion criteria were as follows:
1. Admission to hospital within 12 h (18 h for cardiogenic
shock) of chest pain.
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2. Presence of ≥1 mm ST segment elevation on at least 2
consecutive leads (≥2 mm for V1–V3) of surface ECG
or new left bundle branch block together with chest
pain.
Written informed consent was obtained from all study
patients on admission and the study was approved by the
hospital’s ethics committee.
2.2. Modified ACEF score
A modified ACEF score was calculated for all patients
using left ventricular ejection fraction, age, and creatinine
clearance, which is calculated by the Cockcroft–Gault
equation as follows: age/EF + 1 point for every 10 mL/min
reduction in creatinine clearance below 60 mL/min/1.73
m2 (up to a maximum of 6 points) (7,8).
2.3. Definitions and clinical follow-up
The risk factors, medications, reperfusion times, and
other clinical-demographic properties were obtained from
hospital records and files. On admission, blood samples
were obtained from all patients for hemogram, creatinine,
and troponin I measurements. Following the p-PCI
procedure, a transthoracic echocardiographic evaluation
was performed for all patients (Vivid, GE, Horten, Norway)
during the hospital stay and left ventricular ejection
fractions (LVEFs) were calculated using the modified
Simpson’s formula (9). Surface electrocardiography (ECG)
was recorded before the procedure, at the 90th minute
after the procedure to evaluate ST segment resolution
(STR), and twice daily thereafter until discharge.
Before the procedure all patients are given a 600
mg clopidogrel loading dose p.o., 300 mg chewable
aspirin p.o., and 10,000 U standard heparin I.V. (60 U/
kg for patients who received tirofiban). Application
of preprocedural tirofiban was left to the operator’s
preference and angiographic properties. All percutaneous
interventions were performed by high patient volume
operators by the femoral artery route, using standard
techniques. Either direct stenting or conventional stenting
was applied according to coronary anatomy, lesion
properties, and operator’s preference. Postprocedural
TIMI flow, myocardial blush grade (MBG), and the
presence of distal embolization (DE) were recorded. The
patients were followed in the coronary intensive care unit
after hemodynamic stabilization was achieved. All patients
were given 75 mg/day klopidogrel p.o. and 150 mg/day
aspirin p.o. after the procedure.
Glomerular filtration rate (GFR) was calculated
according to the Cockcroft–Gault formula. No reflow was
defined as the presence of TIMI <3 flow in the absence
of postprocedural spasm, dissection, or other secondary
reasons. Distal embolization was diagnosed in the presence
of a distal filling defect with an abrupt “cut-off ” in one or
more peripheral coronary branches of the IRA. MBG was
evaluated according to preestablished criteria (10). STR

was evaluated from the postprocedural 90th minute ECG;
>70% STR was defined as complete and <30% STR was
called no resolution (11).
2.4. Clinical end-points
One year of clinical follow-up was recorded from
outpatient records, rehospitalization records, and phone
calls with all study patients. Survival status of the patients
who could not be reached otherwise was confirmed from
the institution of statistics and population directorate.
Although the data collection was retrospective in our
study, long term follow-up was performed prospectively.
The patients were called regularly every 3–6 months and
134 patients (6%) whose records could not be reached
despite all efforts were labeled as lost to follow-up during
the long term and excluded from the study.
The main objective of this study was to investigate
the possible role of mACEF scores in the prediction of
1-year outcomes of STEMI patients treated with p-PCI.
The primary end-point was major adverse cardiac and
cerebrovascular events (MACCEs), defined as a composite
of cardiac mortality, stroke, reinfarction, stent thrombosis,
and target vessel revascularization (TVR). Cerebrovascular
events, including stroke, transient ischemic attacks, and
reversible ischemic neurologic deficits, were considered.
All repeat revascularization procedures on the index vessel
were recorded as TVR. Stent thrombosis was defined based
on angiographic documentation of a complete occlusion
(TIMI grade 0 or 1 flow) or angiographic documentation
of a flow-limiting thrombus (TIMI grade 1 or 2 flow) (11).
2.5. Statistics
Continuous variables were expressed as mean ± SD or
median (interquartile range) and categorical variables
were given as percentages. The differences between
continuous variables were evaluated by analysis of variance
or Kruskal–Wallis test as appropriate and the differences
between categorical variables were evaluated by chi-square
or Fisher exact test as appropriate. One-year survival was
evaluated by Kaplan–Meier survival analysis and the
difference between two curves was evaluated by log-rank
test. Receiver operating characteristic (ROC) analyses
were used to compare the performance and prognostic
power of the SS and CSS for 1-year clinical outcomes.
The predictive validities were quantified as the area
under the ROC curves (c-statistics), and the comparisons
of c-statistics were performed with MedCalc statistics
software (version 11.3.8.0, Mariakerke, Belgium). P < 0.05
was accepted as statistically significant in all analyses. All
statistical analyses were performed with SPSS 11.5 (SPSS
Inc., Chicago, IL, USA).
3. Results
The patients were grouped according to mACEF tertiles.
Baseline characteristics are given in Table 1. In patients
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Table 1. Baseline clinical and angiographic characteristics according to mACEF tertiles.
Variables
Age (years)
Male, %
Diabetes, %
Hypertension, %
Smoking, %
Dyslipidemia, %
Family history of CAD, %
Previous history of CAD, %
Chronic renal disease, %
Preinfarction angina, %
Out-of-hospital cardiac arrest, %
Killip class ≥II, %
Cardiogenic shock, %
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
Pain to balloon time, min
Door to balloon time, min
Heart rate, /min
LV-EF, %
LDL-cholesterol, mg/dL
HDL-cholesterol, mg/dL
Triglyceride, mg/dL
Estimated GFR, mL/min/1.73 m2
Anterior MI, %
IRA, %
LMCA
LAD
LCx
RCA
Diseased vessels, %
One vessel
Two vessels
Three vessels
Initial patency in IRA (TIMI 2/3), %
CTO in non-IRA, %
Total stent length, mm
Stent diameter, mm
Bare metal stent, %
Direct stenting, %
Postprocedural TIMI-III flow, %
Postprocedural TMBG-II/III, %
Postprocedural cTFC
Angiographic no-reflow, %
Electrocardiographic no-reflow, %

mACEF < 1.03
(n = 544)
45.7 ± 7.2
87.9
16
25.4
71
47.4
28
7.2
0
25.6
1.3
7
0.7
126 ± 21
76 ± 13
136 ± 100
30.5 ± 6.6
75 ± 13
52 ± 5.7
121 ± 38
37 ± 11
158 ± 108
100 ± 21
40.4

mACEF 1.03–1.37
(n = 545)
57.1 ± 8.2
84.8
20.4
41.5
57.2
39.4
19.3
9.2
0
27.2
1.8
11.9
2
132 ± 28
78 ± 17
160 ± 115
30.3 ± 10.2
76 ± 15
48 ± 66
113 ± 36
38 ± 11
136 ± 88
92 ± 19
46.8

mACEF > 1.37
(n = 543)
67.2 ± 9.9
68
33.3
56
36.6
33
18
15.1
9.4
24.5
4.1
30.2
11.8
133 ± 40
78 ± 24
206 ± 126
31.6 ± 7.4
78 ± 19
41.7 ± 7.8
105 ± 38
41 ± 14
120 ± 63
72 ± 28
59.3

0.2
41.4
15.8
40.6

0.4
47.2
13.6
37.1

0.6
58.6
10.3
30

69.5
24.8
5.7
30.9
4.6
18
3.0
95.1
25
98.9
64.2
19.3 ± 6.4
1.1 or 10.8
16.7

60.4
29.4
10.3
25.3
5.9
18
3.0
94.5
18.3
93.2
50.8
23 ± 12.1
6.8 or 20
33.6

49
36.5
14.5
17.5
11.2
20
3.0
96.5
16.6
79.4
24.4
29.9 ± 18.3
20.6 or 44.2
61.9

P-value of trend
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.690
0.003
<0.001
<0.001
0.001
0.030
<0.001
0.018
0.007
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

<0.001

<0.001
<0.001
<0.001
0.005
0.582
0.287
0.001
<0.001
<0.001
<0.001
<0.001
<0.001

CAD: Coronary artery disease, LV-EF: left ventricular ejection fraction, LDL: low density lipoprotein, HDL: high density lipoprotein,
IRA: infarct related artery, CTO: chronic total occlusion, TFC: TIMI frame count, TMBG: TIMI blush grade.
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with the highest mACEF tertile, out-of-hospital cardiac
arrest (1.3%, 1.8%, and 4.1% consecutively; P = 0.003),
Killip class ≥ II (P < 0.001), and cardiogenic shock were
more common and EF was lower (P < 0.001). Moreover,
pain to balloon times were longer in the mACEF > 1.37
group.
Of the angiographic properties, LAD lesion and
three-vessel disease were more common in the highest
mACEF tertile group. The lesions were also more complex
(long lesion, chronic total occlusion, etc.) in the mACEF
> 1.37 group. When procedural success is concerned,
angiographic and electrocardiographic no-reflow was
more common, stent lengths were longer, and direct
stenting was less common.
In the 1-year follow-up, there was a statistically
significant difference between cardiac mortality, TVR,
stroke, reinfarction, and MACCEs of the groups (Table 2),
while the rates of stent thrombosis were similar. Predictive
values and c-indices are given in Table 3.

4. Discussion
The results of the present study demonstrate that the
modified ACEF score may accurately identify 1-year
major adverse cardiovascular-cerebrovascular events,
particularly cardiac death and stroke in STEMI patients
treated with p-PCI.
Coronary artery disease is the most common cause of
death throughout the world. According to the guidelines
of the European Society of Cardiology, one of every
6 men and 7 women dies from MI (12). STEMI is an
important part of the acute coronary syndromes. Inhospital mortality rates ranged between 7% and 10% (2).
With the increased application of p-PCI and developing
pharmacological approaches, early and late mortality rates
decreased significantly in patients with STEMI. However,
the rates of mortality reduction differ significantly between
trials, which emphasizes the importance of correct risk
stratification. In patients with STEMI, previous MI, door
to balloon time, the presence of diabetes, anemia, chronic

Table 2. One-year clinical outcomes in patients with STEMI according to mACEF score.
mACEF <
1.03

mACEF
1.03–1.37

mACEF >
1.37

P-value*

P-value**

P-value I
vs. II*

P-value I
vs. III*

P-value II
vs. III*

Cardiac mortality

4 (0.7)

8 (1.5)

114 (21)

<0.001

<0.001

0.234

<0.001

<0.001

TVR

62 (11.4)

94 (17.2)

97 (17.9)

<0.001

0.003

0.006

<0.001

0.113

Stroke

2 (0.4)

2 (0.4)

12 (2.2)

0.001

0.002

0.985

0.003

0.005

Reinfarction

16 (2.9)

20 (3.7)

38 (7.0)

<0.001

0.001

0.473

<0.001

0.003

Stent thrombosis

12 (2.2)

11 (2.0)

13 (2.4)

0.708

0.833

0.863

0.527

0.434

MACCE

78 (14.3)

113 (20.7)

230 (42.4)

<0.001

<0.001

0.007

<0.001

<0.001

Variables (n and %)

*P-value for trend and between dual mACEF tertiles determined by log-rank test, **P-value for trend determined by chi-square test.

Table 3. Predictive values for MACCE.
c-index

95% CI

P-value

Cardiac mortality

0.882

0.851–0.913

<0.001

TVR

0.556

0.519–0.594

0.004

Stroke

0.803

0.677–0.928

<0.001

Reinfarction

0.627

0.560–0.694

<0.001

Stent thrombosis

0.506

0.418–0.594

0.901

MACCE

0.689

0.659–0.720

<0.001

TVR: Target vessel revascularization, MACCE: major advanced cardiac and cerebrovascular
events.
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renal failure, and ejection fraction on admission are the
main predictors of mortality. Risk scores such as TIMI,
GRACE, PAMI, Zwolle, or CADILLAC are commonly
applied as mortality indicators (3–6,13,14). Beyond clinical
data, angiographic data are also used to predict the longterm prognosis, such as the SYNTAX score (15). However,
all of these risk scoring systems have disadvantages.
The ACEF score is a simple method calculated using
only age, creatinine clearance, and ejection fraction. In a
multicenter study by Biondi-Zoccai et al., early and lateterm complication rates were higher during complex
coronary interventions (bifurcation lesions) in the high
ACEF group (16). Pyxaras et al. identified high ACEF
value to be an independent predictor of MACCE in
patients with heavily calcific coronary lesions (17). In
another study, Andò et al. determined high ACEF value to
be an independent predictor of acute kidney injury after
p-PCI (18).

In the present study, we identified that high mACEF
value was associated with adverse clinical events during
1-year follow-up in patients treated with p-PCI.
Our study has some important limitations. Although
the follow-up of all patients was performed prospectively,
this study has a retrospective and single-center design. In
order to prevent bias, in-hospital and follow-up data were
collected by different investigators. Secondly, only patients
with acute STEMI who underwent p-PCI were enrolled.
Thus, the results of this study may not be extrapolated
to other patient groups admitted with acute coronary
syndrome or to patients not treated with PCI. A large-scale
multicenter study is required to evaluate the effectiveness
of the mACEF score in the risk stratification of other
patient groups.
In conclusion, the modified ACEF score is a predictor
of cardiac mortality, TVR, stroke, reinfarction, and
MACCE during 1-year follow-up.
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